Abstract
A 60-year-old woman weighing 55 kg presented to the clinic with a 4-month history of sores in her mouth and on her chest. Skin biopsy showed a sparse, superficial, perivascular dermatitis with suprabasal acantholysis. Direct immunofluorescence was positive for IgG and C3 in an intercellular pattern. The patient was started on prednisone at 80 mg per day by an outside dermatologist 1 month prior to referral. Her disease flared when she attempted to taper the prednisone below 80 mg per day, with painful erosions that interfered with eating on her left and right buccal mucosa, and on the left side of her mouth, as well as extensive erosions on her chest and back, and some erosions on her legs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043–6.
Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov. 2006;5(7):564–76.
Zakka LR, Shetty SS, Ahmed AR. Rituximab in the treatment of pemphigus vulgaris. Dermatol Ther. 2012;2(1):17.
Kanwar AJ, Vinay K, Sawatkar GU, et al. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol. 2014;170(6):1341–9.
Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6):545–52.
Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148(9):1031–6.
Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(2):613–20.
Dupuy A, Viguier M, Bedane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol. 2004;140(1):91–6.
Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol. 2004;51(5):817–9.
Charles P, Neel A, Tieulie N, et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology. 2014;53(3):532–9.
Pearce F, Lanyon P. Long-term efficacy and safety of rituximab in ANCA-associated vasculitis: results from a UK tertiary referral center. British Society for Rheumatology annual meeting 2014, Abstract 333.
Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). 25 Sep 2013. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM369436.pdf. Accessed 15 Apr 2014.
Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345(10):747–55.
Li N, Zhao M, Hilario-Vargas J, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest. 2005;115(12):3440–50.
Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60(4):595–603.
Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol. 2002;138(9):1158–62.
Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355(17):1772–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Robinson, E.S., Werth, V.P. (2015). A 60-Year-Old Woman with Pemphigus Vulgaris Refractory to High-Dose Prednisone. In: Murrell, D. (eds) Clinical Cases in Autoimmune Blistering Diseases. Clinical Cases in Dermatology, vol 5. Springer, Cham. https://doi.org/10.1007/978-3-319-10148-4_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-10148-4_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-10147-7
Online ISBN: 978-3-319-10148-4
eBook Packages: MedicineMedicine (R0)